Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal oral glucose-lowering monotherapy in non-overweight African adults with recently diagnosed type 2 diabetes
PACTR202603837093463Phase 4Not yet recruiting
- Sponsor
- National Institute for Health and Care Research
- Start
- Apr 2026
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4 trial of metformin, glimepiride and sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by National Institute for Health and Care Research. Primary endpoint: Mean change in glycated haemoglobin (HbA1c) from baseline to 12 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
metforminglimepiridesitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR202603837093463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202603837093463.